乐普医疗 reported revenue of ¥3.21B for the period ended 2026-06-30, -4.6% year on year. Net income was ¥0.46B, a 14.2% net margin on a 60.9% gross margin. The largest revenue line is 医疗器械 at 53% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.21B | -4.6% |
| Gross profit | ¥1.96B | — |
| Operating income | ¥0.50B | — |
| Net income | ¥0.46B | -34.7% |
| Gross margin | 60.9% | Net margin 14.2% |
| Revenue Q/Q | -7.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医疗器械 | ¥1.71B | 53.4% |
| 药品 | ¥0.96B | 29.9% |
| 医疗服务及健康管理 | ¥0.54B | 16.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.26B | 39.1% |
| R&D | ¥0.48B | 14.8% |
| SG&A | ¥0.80B | 24.8% |
| Tax & other | ¥0.04B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥26.17B |
| Total liabilities | ¥8.31B |
| Shareholders' equity | ¥17.86B |
| Equity / assets | 68.3% |
| Operating cash flow | ¥0.36B |
| Capital expenditure | ¥0.33B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 139% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术 ・ 华测检测 ・ 新宁物流 ・ 北陆药业 ・ 网宿科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies